U.S. markets close in 1 hour 15 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
101.87+0.44 (+0.43%)
As of 02:45PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close101.43
Bid101.91 x 1200
Ask101.92 x 800
Day's Range100.86 - 102.30
52 Week Range61.16 - 105.69
Avg. Volume4,814,263
Market Cap466.63B
Beta (5Y Monthly)0.20
PE Ratio (TTM)41.58
EPS (TTM)2.45
Earnings DateN/A
Forward Dividend & Yield1.03 (1.02%)
Ex-Dividend DateAug 18, 2023
1y Target Est103.96
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-27% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novo Nordisk A/S
    Analyst Report: Novo Nordisk A/SWith roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
    Fair Value
    Economic Moat
    20 hours agoMorningstar
View more